WASHINGTON — Several drugmakers are expected to sign pricing agreements with the Trump administration on Friday, according to four people familiar with the plans, who were not authorized to speak publicly.
The agreements would be the latest in a series of deals in which pharmaceutical companies agree to lower drug prices and invest more domestically in exchange for avoiding tariffs and other benefits, such as fast-tracked drug reviews.
The terms of the deals thus far have remained private, leaving their full impact unknown.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
To read the rest of this story subscribe to STAT+.
